Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

Food and Healthcare Press Releases Thursday April 2, 2020 09:23
SHIJIAZHUANG China--2 Apr--PRNewswire/InfoQuest

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in line with Thailand's modern herbal medicine standards registration. The registration certificate number is i6300037/63(H).

1. The functional indications of Lianhua Qingwen Capsule approved by the Thai FDA are:It can be used for the treatment of influenza with fever, muscle aches, nasal congestion, cough, sore throat, and headache;

2. According to the theory of traditional Chinese medicine, it has the effect of detoxification & let off heat, and can be used to treat a cold with symptoms of fever, muscle pain, nasal congestion runny nose, cough, and sore throat.

Lianhua Qingwen is a patented product of Yiling Pharmaceutical Co., LTD., a category of national essential medicine catalogue and national medical insurance catalogue. It is mainly used for the treatment of cold and flu-related diseases. Lianhua Qingwen products have been listed in the cold and flu-related diseases treatment program by the National Health Commission and the State Administration of Traditional Medicine of China for many times. In 2020, Lianhua Qingwen Capsules/Granules were listed as the recommended drug in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme" (Trial version IV/V/VI/VII) which was jointly issued by the National Health Commission and the State Administration of Traditional Medicine of China.

Lianhua Qingwen Capsule has been approved by the Thai FDA for the registration of modern herbal medicine, which indicates that the company has the qualification to sell products as a drug in the Thai market and will have a positive impact on its overseas market expansion.

Up to now, in addition to Thailand, Lianhua Qingwen Capsules have been registered in Hong Kong (SAR of China), Macao (SAR of China), Brazil, Indonesia, Canada, Mozambique, and Romania as "Chinese patent medicine", "medicine", "plant medicine", "natural health products", "food supplement" and other identities, and obtained the marketing authorisation.

Read more: http://www.digitaljournal.com/pr/4628222#ixzz6IFN1AkBx

Latest Press Release

DERMALOG Temperature Check: Greater Safety for Medical Practices

Due to the corona pandemic, general practitioners and specialists face the challenge of maintaining their practice without putting patients and staff at increased risk of infection. In Frankfurt, Germany, a medical practice has implemented health...

KBank and Thammasat University Hospital launch TUH for All app

KBank and Thammasat University Hospital launch TUH for All app, highlighting TUH OPD Online – the remote delivery of healthcare services – in step with the 'New Normal’ environment KASIKORNBANK (KBank) has teamed with Thammasat...

Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

- Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect...

Lose Weight the Smart Way: Dietitians Share 10 Tips for Healthy Eating

By: Susan Bowerman M.S.,RD,CSSD, CSOWM, FAND – Senior Director, Worldwide Nutrition Education and Training Tip 1: Don’t just focus on weight loss. Focus on a healthy diet. “People should not focus only on body weight, they should...

Cigna Study Shows Financial and Social Well-being Declines during COVID-19 Crisis

Cigna's (NYSE:CI) International Markets business, in partnership with Kantar, today published its firstCigna COVID-19 Global Impact Study. Part of Cigna's annual 360 Well-Being Survey, this research is the first in a new series of studies from Cigna to...

Related Topics